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2A 2,3-diphenylpyrido[1,2-a] pyrimidin-4-one derivative inhibits 
specific angiogenic factors induced by TNF-α
ABSTRACT
Low-grade chronic inflammation is a key process of angiogenesis in tumour progression. We 
investigated whether a synthetic analogue of apigenin, the 2-(3,4-dimethoxyphenyl)-3-phenyl-
4H-pyrido[1,2-a] pyrimidin-4-one (called DB103), interfered with the mechanisms involved 
in the angiogenic process induced by the inflammatory cytokine tumour necrosis factor 
(TNFα). In endothelial cells, DB103 but not apigenin reduced the TNFα-induced oxidative 
stress. DB103 inhibited the activation of ERK1/2 but not JNK, p38 and Akt kinases, while 
apigenin was not so selective because it inhibited essentially all examined kinases. Similarly, 
apigenin inhibited the TNFα-induced transcription factors CREB, STAT3, STAT5 and NF-
B, while DB103 acted only on NF-B. DB103 inhibited the induced-release of angiogenic 
factors such as monocyte chemotactic protein-1, interleukin-6 (IL-6) and angiopoietin-2 but 
not IL-8, while apigenin reduced the IL-6 and IL-8 release. DB103 revealed a better ability 
than apigenin to modulate proangiogenic responses induced by an inflammatory 
microenvironment.  
Keywords: apigenin synthetic analogue; cell signalling; inflammation; angiogenesis.
31. Introduction
It is known that chronic inflammation potentiates or promotes cancer development, growth, 
and progression (Yao et al. 2016). Excessive production of inflammatory cytokines stimulates 
proliferation of endothelial cells (ECs) culminating in sustained tumour angiogenesis (Huang and Blobe 
2016, Yao et al. 2016). The finding of high cytokine serum levels in cancer patients supported 
the opportunity to promote anti-inflammatory therapies in an attempt to counteract cancer 
progression. The tumour microenvironment is full of pro-inflammatory and proliferative 
factors including tumour necrosis factor (TNF)-α, interleukin (IL)-6, vascular endothelial 
growth factors (VEGF), metalloproteases, adhesion molecules and chemokines, whose 
expression is mainly regulated by the transcription nuclear factor-B (NF-B), which plays a 
key role both in the inflammatory process and in the cancer development (Pikarsky et al. 
2004). TNF-α is angiogenic in vivo, while in vitro it does not directly induce EC migration 
and proliferation but promotes the angiogenic process only in the presence of growth factors 
and protease (Liu et al. 2016, Salvatore et al. 2017). 
An increased intake of dietary flavonoids is associated with a decreased risk of cardiovascular 
diseases and cancer (Hussain et al. 2016, Lewandowska et al. 2016). Flavonoids have been 
found to inhibit angiogenesis through multiple mechanisms including inhibition of hypoxia-
signalling cascades, down-regulation of the NF-B pathway, and direct interaction with 
intracellular signalling pathways of growth factor-receptors (Hussain et al. 2016, 
Lewandowska et al. 2016). There is to point out that most in vitro studies on flavonoid 
antiangiogenic properties generally exploited high concentrations of specific compounds until 
to 100 µmol/L (Zern and Fernandez 2005, Romagnolo and Selmin 2012). Hence apparent 
effects seen only at the limit of toxicity should be interpreted with caution. Thanks to their 
interesting functional properties, flavonoids have become a starting point for chemists to 
develop new synthetic analogues with improved functional properties than native or natural 
ones. Pursuing our interest in the synthesis of bioisosteres of flavonoids, making structural 
4changes that have been recently described (La Motta et al. 2007), we obtained a novel class of 
2,3-diphenylpyrido[1,2-a]pyrimidin-4-ones (La Motta C. et al. 2013, Del Turco et al. 2015).  
We recently demonstrated (Del Turco et al. 2014). that, in our experimental conditions, 
flavonoid bioisosteres developed in our laboratory and inspired by the apigenin scaffold were 
well-tolerated even at 50 µmol/L, and for longer time, while the endothelial tolerability limit 
of apigenin for 72 hours of incubation was 10 µmol/L (Del Turco et al. 2014).  In particular, 
we discovered that low concentrations of a synthetic derivative (2-(3,4-dimethoxyphenyl)-3-
phenyl-4H-pyrido[1,2-a] pyrimidin-4-one), belonging to this class of bioisosteres and named 
DB103 (Chart 1), inhibited the smooth muscle cell proliferation but not the EC proliferation, 
and in both cell types it did not alter their vitality (Del Turco et al. 2014).
Chart 1. (A) 2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido[1,2-a] pyrimidin-4-one (DB103). 
(B) apigenin.
5From this, it follows that its biocompatibility associated with a more specific functional 
activity than apigenin gives to DB103 improved functional properties. In continuity with what 
we have previously published, here we investigated whether DB103, compared with its 
natural analogue, modulated the inflammatory angiogenesis induced by TNF-α, by affecting 
proliferative factors and signalling pathways. 
62. Material and methods
2.1. Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) except where 
specified. Stock solutions of apigenin and DB103 were dissolved in sterile dimethyl sulfoxide 
(DMSO) and stored at -80 °C at the maximum solubility of 50 mmol/L. Since the final 
concentration of DMSO in the culture medium never exceeded 0.1%, DMSO (0.1%) alone 
served as a control. At this concentration, it did not show any effect on cell viability, cell 
proliferation, or related molecular mechanisms (data not shown).
2.2. Chemical synthesis of DB103
 2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one, (called DB103), was 
synthesized from the key intermediate 2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-
4-one, prepared as reported elsewhere (La Motta et al. 2007). Briefly, the treatment of the 
intermediate with N-bromosuccinimide, in refluxing chloroform, produced the corresponding 
3-bromo derivative that after the reaction with phenylboronic acid in the presence of bis 
(triphenylphosphine)palladium(II) dichloride and Na2CO3, in refluxing toluene, led to the 
target compound DB103.
2.3. Cell cultures and treatments
 ECs were isolated from human umbilical vein endothelial cells, and characterized and 
maintained as described (Lazzerini et al. 2009). ECs were obtained from discarded umbilical 
vein and treated anonymously conforming to the principles outlined in the Declaration of 
Helsinki. Cells were used up to the fifth passage from primary culture. 
If not otherwise indicated, experiments were performed on cells at pre-confluence, and cells 
were pre-treated for 5 minutes with 10 and 50 µmol/L of DB103, 10 µmol/L of apigenin or 
vehicle alone, before stimulation with TNF-α (10 ng/mL) for times that vary according to the 
experimental target. For each experimental condition, no less than 3 replicates had been 
performed. Cellular toxicity by apigenin and DB103 was checked at a range of concentration 
7from 1 µmol/L to 50 µmol/L (data not shown) through the phase contrast microscopy of cell 
morphology and WST-1 assay (Roche Diagnostics, Mannheim, Germany) using the 
manufacturers’ protocol as previously described (Cervelli et al. 2014).
2.4. Detection of intracellular oxidative stress
 ECs were treated with TNF-α at 10 ng/mL in the presence/absence of DB103 or apigenin for 
1 hour and the generation of intracellular ROS was measured with the fluorescent dye 6-
carboxy-2′,7′ dichlorodihydrofluorescein diacetate bis(acetoxymethyl)-ester (C-DCF-DA) 
(Molecular Probes, Inc., Eugene, Oregon, USA) as described (Cervelli et al. 2014). 
2.5. Cell signalling pathway analysis
ECs were plated in 100mm dishes, grown at sub-confluence, and subjected to partial fetal calf 
serum (2%) reduction for 18 hours before the addition of treatments and stimulation with 
TNF-α for 10 minutes. Cells were harvested in lysis buffer in the presence of protease 
inhibitor cocktail set III (Calbiochem, EMD Biosciences, San Diego, CA, USA). Each lysate 
(10 𝜇g of total protein) was analysed with the Milliplex® Map Multi-Pathway 9-plex 
Magnetic Bead Signalling kit (Merck Millipore, Billerica, MA, USA), to detect changes in 
phosphorylation of the kinases [ERK 1/2 (Thr185/Tyr187), JNK (Thr183/Tyr185), p38 
(Thr180/Tyr182) and Akt (Ser473)] and transcription factors [NF-B p65 (Ser536), 
STAT3(Ser727), STAT5A/B (Tyr694/699) and CREB (Ser133)], according to the 
manufacturer’s instructions. Finally, the fluorescence intensity was read on an integrated 
multi-analyte detection platform (high-throughput technology MagPix system, Luminex® 
xMAP® technology, Merck Millipore).
2.6. ELISA analysis of the phospho-NF-B p65 protein
 To confirm the results by the above-mentioned Luminex® xMAP® technology, the 
quantification of phospho-NF-B p65 protein was determined with the PathScan® Phospho-
NF-B p65 (Ser536) Sandwich ELISA Kit (Cell Signalling Technology, Danvers, MA, USA) 
8in the same cell lysates, according to manufacturer’s instructions. Optical density was read in 
a microplate reader at 450 nm.
2.7. IL-6, monocyte chemotactic protein 1 (MCP-1), VEGF-A, Angiopoietin-2(Ang-2) and IL-
8 determination
 After pre-treatment with the indicated compounds for 5 minutes and overnight stimulation 
with TNF-α at 10 ng/mL, culture supernatant samples were collected, frozen and thawed only 
once before the cytokine quantification. The amount of IL-6 and MCP-1 proteins were 
determined using the human IL-6 and MCP-1 Quantikine ELISA kits (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s instructions. The sensitivity of the 
IL-6 and MCP-1 was 0.7 and 1.7 pg/mL, respectively. The quantification of IL-8, VEGF-A 
and Ang-2 was performed with a custom-made Milliplex® Map Human Cytokine/Chemokine 
Magnetic Bead Panel (Merck Millipore). Cell culture supernatant samples were processed 
following the manufacturer’s recommended protocols and read on the Luminex® xMAP® 
platform (Merck Millipore). The sensitivity of VEGF-A, IL-8 and Ang-2 was 8.1, 0.2 and 3 
pg/mL, respectively. 
2.8. Statistical analysis
 The results were expressed as mean ± SD, percentage or median. The percentage of 
inhibition was calculated by the formula (value of positive control – value of sample/ value of 
positive control − value of negative control) × 100. Multiple comparisons were performed by 
one-way ANOVA followed by Bonferroni's post-hoc tests. Values of P < 0.05 were 
considered statistically significant. Data were analysed with the use of statistical software 
SPSS 13.0 (SPSS Inc, Chicago, IL, USA).
93. Results and Discussion 
3.1. DB103 inhibited the TNF-α-induced oxidative stress
 As shown in the Fig.1, ECs stimulated for one hour with TNF-α, produced intracellular 
reactive oxygen species (ROS) and pre-treatment with DB103 at 10 µmol/L strongly inhibited 
their production (61.3% ± 10% of inhibition). Pre-treatment with DB103 at 50 µmol/L 
inhibited in an almost identical manner (data not shown), indicating that the maximum 
inhibition of ROS production was reached at 10 µmol/L. Conversely, pre-treatment with 
apigenin at 10 µmol/L increased ROS burst triggered by TNF-α (37% ± 7% of increase) (Fig. 
1). 
Fig. 1. DB103, but not apigenin, inhibited the TNF-α-induced intracellular ROS generation
 (A) Representative photomicrographs (10x magnifications) of ROS produced in ECs 
incubated for 1 hour with vehicle (a) or with 10 ng/mL of TNF-α (b) in the continued 
presence of DB103 (c) or apigenin (d) at 10 µmol/L. (B) Quantitative analysis of ROS 
expressed as mean ± SD of arbitrary fluorescence units of 3 replicates. #P<0.001 vs. control; 
*P<0.05 and **P<0.01 vs. TNF-α alone. Photomicrographs are representative of three 
experiments performed on different experimental days.
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These results suggest that DB103 has antioxidant properties that are known to be related to 
anti-inflammatory properties (Griffiths et al. 2016). Instead, the ROS increase by apigenin is 
in agreement with that  recently published by Souza et al.(Souza et al. 2017) and, as suggested 
by the authors themselves, could be associated to its pro-apoptotic and anti-proliferative 
properties (Sung et al. 2016, Souza et al. 2017).
3.2. Among the TNF-α-induced kinases, DB103 inhibited only the extracellular signal–
regulated kinase (ERK) 1/2
 We analysed the effects of DB103 on the main protein kinases activated by TNF-α, such as 
MAPKs and Akt kinase that regulate various processes including cell survival, growth and 
angiogenesis. After 10 minutes of stimulation, TNF-α activated the phosphorylation of c-Jun 
N-terminal kinases (JNK), p38, ERK 1/2 and Akt kinases (Fig. 2). DB103 inhibited the 
phosphorylation of ERK 1/2 kinase while it did not alter JNK, p38 and Akt (Fig. 2 A-B). At 
the opposite, apigenin inhibited all examined kinases (Fig. 2A-B). These different effects on 
cell signalling pathways highlight that DB103 is more specific than apigenin.
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Fig. 2. Contrary to apigenin, DB103 inhibited only the TNF-α-induced ERK 1/2 kinase  
 ECs were incubated with vehicle or with TNF-α (10 ng/mL) in the continued presence of 
DB103 or apigenin. Cell lysates were assayed with multiplex technology for the 
phosphorylation of JNK, p38, ERK 1/2 (A) and Akt kinases (B). Results are expressed as 
median fluorescence intensity. Each bar represents the mean of three independent 
experiments, each performed in n = 4 replicates. #P<0.001 vs. control; *P<0.05 and **P<0.01 
vs. TNF-α alone.
12
3.3. Among the TNF-α-induced transcription factors, DB103 inhibited only NF-B
 We evaluated the effect of both compounds on the main transcription factors induced by 
TNF-α. The efficacy of apigenin was remarkable on STAT3, STAT5, NF-B and CREB   
transcription factors (Fig. 3 A-B) while DB103 inhibited only NF-B phosphorylation ( Fig. 
3A). The phospho-NF-B p65 induced by TNF-α was also analysed by the ELISA method,  
confirming the same inhibitory patterns of the two compounds on phospho-NF-B p65 (Fig. 
3C). Once again, the performance of the two compounds was dissimilar.
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Fig. 3. DB103 inhibited only NF-B while apigenin inhibited indiscriminately 
 ECs were incubated with vehicle or with 10 ng/mL of TNF-α in the continued presence of 
DB103 or apigenin. Cell lysates were assayed by multiplex technology for the 
phosphorylation of STAT3, STAT5, NF- B (A) and CREB (B). Results are expressed as 
median fluorescence intensity. Each bar represents the mean of three independent 
experiments, each performed in n = 4 replicates. The phospho-NF-κB p65 was also evaluated 
on cell lysates by an ELISA assay (C). The bars represent the mean ± SD from four replicates. 
°P<0.01 and #P<0.001 vs. control; *P<0.05 and **P<0.01 vs. TNF-α alone.
3.4. DB103 inhibited MCP-1, IL-6 and Ang-2 but not the IL-8 cell release
 As shown in Fig. 4, upon overnight stimulation with TNF-α (10 ng/mL), ECs produced and 
released angiogenic cytokines, but not VEGF-A (data not shown). The absence of VEGF-A in 
the supernatant could be due to the fact that TNF-α-induced VEGF-A expression is not direct 
but it depends by other TNF-α-induced cytokines (Yoshida et al. 1997).. Consequently, since 
its detection requires a longer time of stimulation, the overnight treatment with TNF-α 
resulted insufficient for a sensible detection and a following estimate of the inhibitory 
treatments (data not shown). DB103 inhibited MCP-1 in a concentration-dependent manner, 
while apigenin did not inhibit it (Fig. 4A). MCP-1, which is best known for its role in 
recruiting monocytes/macrophages to the arterial wall, up-regulates the hypoxia-inducible 
factor 1 and consequently induces VEGF-A (Hong et al. 2005) and therefore may indirectly 
contribute to cell proliferation and angiogenesis (Hong et al. 2005, Gacche and Meshram 
2013, Bianconi et al. 2018). Also, IL-6, which resulted to be inhibited by both DB103 and 
apigenin (Fig. 4B), plays a crucial role in the angiogenic process because it upregulates the 
VEGF promoter activity in tumour cells(Loeffler et al. 2005, Huang et al. 2016). DB103, 
contrary to apigenin, reduced in a concentration-dependent manner the TNF-α-induced 
release of Ang-2 (Fig. 4C), a cytokine promoting cell death that, nevertheless, combined with 
VEGF, can promote neo-vascularization (Hashizume et al. 2010). An opposite result was 
obtained about the interference of the two compounds on the TNF-α-induced release of IL-8 
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(Fig. 4D), a chemokine regulated by NF-B transcription factor which activates signal 
transducers and activators that in turn promote angiogenesis (Waugh and Wilson 2008, Zhang 
et al. 2012). Although DB103 inhibited strongly the p65 phosphorylation, it unreduced IL-8 
release (Fig. 4D), suggesting that other post-transcriptional mechanisms can be affected by 
DB103 with consequent absence of a net effect on production and release of IL-8 (Hoffmann 
et al. 2002, Wang et al. 2012). On the other hand, we cannot exclude that DB103 can exert a 
stimulating action and favouring the IL-8 production through other cell-signalling pathways, 
which we have not investigated here.
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Fig.  4. DB103 inhibited IL-6, MCP-1 and Ang-2 but not IL-8 cell release
ECs were incubated for 24 hours with vehicle or with 10 ng/mL of TNF-α in the continued 
presence of DB103 or apigenin. MCP-1 (A), IL-6 (B), Ang-2 (C) and IL-8 (D) expression 
were measured on cell supernatant by ELISA assay. Each bar represents the mean of three 
independent experiments, each performed in six replicates. ANOVA with Bonferroni’s post 
hoc comparison. #P<0.001 vs. control; *P<0.05 and **P<0.01 vs. TNF-α alone.
4. Conclusion
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 DB103 modulated the expression of several angiogenic factors induced by TNF-α as 
illustrated in the Fig. 5. These proliferating factors, including TNF-α, accumulate in the 
cancer-surrounding microenvironment and generate a low-grade, chronic inflammation, 
which is a crucial process involved in tumour progression (Candido and Hagemann 2013). 
DB103 revealed a superior ability than apigenin to modulate the angiogenic process induced 
by TNF-α. 
In conclusion, although DB103 does not block the growth factors-induced physiological 
angiogenesis, as we previously published (Del Turco et al. 2014), it may hinder a tumour 
advancing by reducing factors and processes triggered by chronic and persistent inflammation 
of the tumour environment, characterized by the presence of cytokines and chemokines, all 
involved in the angiogenic development. Therefore, our compound could assist the action of 
current anti-proliferative drugs modulating the low-grade chronic inflammatory condition. 
Further studies in animal models will prove the robustness of this dietary supplement as a 
potential candidate for developing functional foods, utilisable to contrast the pathological 
angiogenic responses associated with the secretion of inflammatory cytokines in cancer.
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Fig. 5. Effect of DB103 and apigenin on different TNF-α signalling pathways and their 
molecular targets
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